EUDA Health (EUDA) said Tuesday it signed a memorandum of understanding to establish a collaboration with GO POSB Organoids and Shenzhen Innovation Immunotechnology on next-generation therapies derived from induced pluripotent stem cells.
The parties plan to collaborate on the development, manufacturing and commercialization of off-the-shelf oncology cell therapies for cancer-treatment and wellness applications, according to a statement.
Price: 20.00, Change: +1.00, Percent Change: +5.26
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments